STADA, SBP Group Signed Biosimilars Partnership
The agreement grants STADA exclusive rights to market CTTQ-developed biosimilars in European and CIS markets.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Do you believe corporate partnerships between global pharmaceutical firms improve patient access to affordable medication?
STADA Arzneimittel and SBP Group have formed a strategic partnership to expand patient access to high-value biological medicines. Under the agreement, CTTQ will develop and manufacture biosimilar candidates while STADA secures exclusive sales rights in the EU, UK, Switzerland, and the CIS.
Why it matters
This deal leverages specialized manufacturing in China to bolster the European biosimilar supply chain. It provides STADA with a pipeline of biological drugs to compete in major international markets while allowing for potential expansion into the US and Gulf states.
The partnership spans sales rights across the EU, Switzerland, the UK, and the CIS, with options for the US and Gulf Cooperation Council. The agreement defines the roles for STADA and CTTQ, yet the specific number of biosimilar assets included remains undisclosed.
The players
STADA Arzneimittel
A Germany-based pharmaceutical company focused on generics, specialty products, and consumer health.
SBP Group
A China-based pharmaceutical parent organization operating large-scale drug research and manufacturing.
CTTQ
The innovative pharmaceutical subsidiary of SBP Group responsible for research, development, and manufacturing.
The details
The collaboration divides operational responsibilities along core competencies: SBP Group's subsidiary CTTQ handles all clinical development, manufacturing, and supply chain logistics for the biosimilar candidates. STADA holds the marketing authorizations and manages all commercial distribution in its designated territories. This structure allows STADA to scale its biological medicine portfolio without the capital expenditure of in-house manufacturing development.
Timeline
September 28, 2026: STADA and SBP Group announced the strategic partnership.
Market Landscape
This deal follows a broader industry trend where Western pharmaceutical distributors partner with specialized manufacturers to access biological drug pipelines. By outsourcing complex development and manufacturing to CTTQ, STADA secures a competitive position in the growing biosimilar market.
Operators in the pharmaceutical space should monitor the expansion of these cross-border supply chains for potential cost reductions in high-value biological products. Consider evaluating your own distribution agreements against this model of separating manufacturing and marketing rights.
The takeaway
This partnership highlights the trend of leveraging international manufacturing capacity to secure market share in high-barrier biological segments. Review your regional distribution agreements to identify whether you are effectively leveraging external development capabilities.
Further reading
For additional context on the competitive dynamics of the sector, visit the Healthcare section.
Source note: This article includes information reported by Thepharmaletter.
Live Poll
Do you believe corporate partnerships between global pharmaceutical firms improve patient access to affordable medication?
